Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ENTA
- Price
- 13.86
- Stock movement up
- +0.01 (0.07%)
- Company name
- Enanta Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 402.20M
- Ent value
- 567.67M
- Price/Sales
- 6.00
- Price/Book
- 3.18
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 16.17%
- 1 year return (CAGR)
- 84.80%
- 3 year return (CAGR)
- -36.08%
- 5 year return (CAGR)
- -24.02%
- 10 year return (CAGR)
- -4.30%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ENTA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.00 |
| Price to Book | 3.18 |
| EV to Sales | 8.48 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 29.02M |
| EPS (TTM) | -2.49 |
| FCF per share (TTM) | -0.64 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 66.98M |
| Gross profit (TTM) | 48.37M |
| Operating income (TTM) | -73.06M |
| Net income (TTM) | -71.54M |
| EPS (TTM) | -2.49 |
| EPS (1y forward) | -2.63 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 72.21% |
| Operating margin (TTM) | -109.08% |
| Profit margin (TTM) | -106.80% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 37.44M |
| Net receivables | 8.49M |
| Total current assets | 198.68M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 329.50M |
| Accounts payable | 1.89M |
| Short/Current long term debt | 57.07M |
| Total current liabilities | 44.73M |
| Total liabilities | 202.91M |
| Shareholder's equity | 126.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -14.17M |
| Capital expenditures (TTM) | 4.29M |
| Free cash flow (TTM) | -18.46M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -56.51% |
| Return on Assets | -21.71% |
| Return on Invested Capital | -55.08% |
| Cash Return on Invested Capital | -14.22% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 13.89 |
| Daily high | 14.12 |
| Daily low | 13.65 |
| Daily Volume | 105K |
| All-time high | 126.37 |
| 1y analyst estimate | 19.25 |
| Beta | 0.99 |
| EPS (TTM) | -2.49 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 May 2026 |
Downside potential
Loading...
Downside potential data
| ENTA | S&P500 | |
| Current price drop from All-time high | -89.03% | -1.82% |
| Highest price drop | -96.63% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -48.27% | -10.84% |
| Avg time to new high | 42 days | 12 days |
| Max time to new high | 1913 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
402.20M
Marketcap category
Small-cap
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Employees
120
Website
Investor relations
-
SEC filings
CEO
Jay R. Luly
Country
USA
City
Watertown
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page